AD Detect and Prevent at the Alzheimer’s Association Academy – 10-11 December 2019

The Alzheimer's disease (AD) Detect and Prevent project was presented at the Alzheimer’s Association Academy that was held on 10 - 11 December 2019 in Brussels, Belgium.

On this occasion, Kim Baden-Kristensen (Brain+) and Younes Tabi (Oxford University) presented the objectives of the project as well as the issues that the AD Detect and Prevent tool aims to address. Furthermore, the audience was introduced to the ‘Sea Hero Quest’ as well as the gamified AD test that is currently under development.

The event brought together a wide range of academics, patient representatives and healthcare stakeholders to address key questions in the AD and dementia space. Specific topics included the role of new technologies in diagnosing AD, models of patient engagement in dementia, ethical issues in dementia research and patient involvement in medicines development.

“I was positive about the interest and enthusiasm shown by the various national patient advocacy groups represented at the academy when we presented and demonstrated the ADDP project. There were also many good curious and important questions being raised that we in the consortium can take home and digest, and use as valuable input. Most important for me was the fact that what we are working on resonated with the patient advocates, and there was a confirmation that there is a need for this type of innovative product.” says Kim Baden-Kristensen, CEO and co-founder of Brain+.

The presentation introducing AD Detect and Prevent can be accessed here.

Kim from Brain+ discussing ‘Brain health and prevention’ during IMI Stakeholder Forum 2019

The IMI Stakeholder Forum 2019 took place on Wednesday 12 June in Brussels, Belgium. The theme was "Brain health and disease in the digital era - 2020 & beyond".

IMI stands for Innovative Medicines Initiative and is the world’s biggest public-private partnership in the life sciences. It is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

We’re pleased that Kim Baden-Kristensen, CEO of Brain+ and coordinator of the AD Detect Prevent consortium, was asked to be part of the discussion panel that day on Brain health and prevention.

Brain + is a digital therapeutics company that helps people, who are suffering from neurological disorders, -disease and brain injuries to restore their fundamental cognitive brain functions to full health and functionality via a therapeutics platform.
In the video below Kim explains more about the mission of Brain+ and how they want to achieve that mission.



The discussion panel on ‘Brain health and prevention’ was about the shift of healthcare from reactive treatment and care to early detection and prevention, and the increasingly active role patients play in managing their health. In this session different stakeholders discussed how they are engaging with digital health technologies, and how they are demonstrating reliability and performance of these technologies while assuring compliance with legal, regulatory and ethical requirements.

Here you can find a list of the different stakeholders that were part of this panel (p. 1).

In the video below we included 3 questions that were asked by the moderator and answered by Kim, which were:



1) How do we stop people diagnosing themselves with Dr. Google results?
2) Who’s going to pay for digital solutions?
3) What do you think IMI (as a public-private partnership) should be doing?

If you’d like to see the full discussion on this ‘Brain health and prevention’ session click here.

AD Detect and Prevent at Brain Conference “Understanding and targeting Alzheimer’s disease”

The AD Detect and Prevent consortium was present at the Brain Conference “Understanding and targeting Alzheimer's disease” that was held on 5-8 May 2019 in Rungstedgaard, Denmark. This conference, organized by the Federation of European Neuroscience Societies (FENS), brought together leading brain researchers and scientists in order to, amongst other issues, exchange views on challenges connected to Alzheimer’s Disease (AD) as well as how to address knowledge gaps in the field of AD research. Various presentations on the latest clinical trials and the requirement of biomarkers for early risk assessment were held during the meeting.

On this occasion, Ulrik Ditlev Eriksen, co-founder of Brain+, delivered a presentation on how the EU-funded AD Detect and Prevent project aims to enhance the early detection of AD and address risk factors connected to Alzheimer’s Dementia. AD Detect and Prevent also took part in the Poster Session that was held on 6 May.

Further information on the event can be accessed here.